STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

Cassava Sciences, Inc. (NASDAQ:SAVA) Q3 2024 Earnings Call Transcript November 7, 2024 Cassava Sciences, Inc. beats earnings ...

Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...

Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024$149.0 Million in Cash and Cash Equivalents at September 30, ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.